231 related articles for article (PubMed ID: 28236846)
1. The prevention of benign prostatic hyperplasia (bph).
Roper WG
Med Hypotheses; 2017 Mar; 100():4-9. PubMed ID: 28236846
[TBL] [Abstract][Full Text] [Related]
2. Proliferative disorders of the aging human prostate: involvement of protein hormones and their receptors.
Untergasser G; Rumpold H; Hermann M; Dirnhofer S; Jilg G; Berger P
Exp Gerontol; 1999 Apr; 34(2):275-87. PubMed ID: 10363793
[TBL] [Abstract][Full Text] [Related]
3. Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate.
Krieg M; Bartsch W; Thomsen M; Voigt KD
J Steroid Biochem; 1983 Jul; 19(1A):155-61. PubMed ID: 6193338
[TBL] [Abstract][Full Text] [Related]
4. Clinical and experimental studies of benign prostatic hyperplasia.
Coffey DS; Walsh PC
Urol Clin North Am; 1990 Aug; 17(3):461-75. PubMed ID: 1695775
[TBL] [Abstract][Full Text] [Related]
5. Role of stroma in carcinogenesis of the prostate.
Cunha GR; Hayward SW; Wang YZ
Differentiation; 2002 Dec; 70(9-10):473-85. PubMed ID: 12492490
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of CYR61, an extracellular matrix signaling protein, in human benign prostatic hyperplasia and its regulation by lysophosphatidic acid.
Sakamoto S; Yokoyama M; Zhang X; Prakash K; Nagao K; Hatanaka T; Getzenberg RH; Kakehi Y
Endocrinology; 2004 Jun; 145(6):2929-40. PubMed ID: 14988385
[TBL] [Abstract][Full Text] [Related]
7. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens.
Monti S; Di Silverio F; Iraci R; Martini C; Lanzara S; Falasca P; Poggi M; Stigliano A; Sciarra F; Toscano V
J Clin Endocrinol Metab; 2001 Apr; 86(4):1700-6. PubMed ID: 11297606
[TBL] [Abstract][Full Text] [Related]
8. Lysophosphatidic acid stimulates phospholipase D activity and cell proliferation in PC-3 human prostate cancer cells.
Qi C; Park JH; Gibbs TC; Shirley DW; Bradshaw CD; Ella KM; Meier KE
J Cell Physiol; 1998 Feb; 174(2):261-72. PubMed ID: 9428812
[TBL] [Abstract][Full Text] [Related]
9. Androgens and estrogens in benign prostatic hyperplasia: past, present and future.
Nicholson TM; Ricke WA
Differentiation; 2011; 82(4-5):184-99. PubMed ID: 21620560
[TBL] [Abstract][Full Text] [Related]
10. Relationship between the prostatic tissue components and natural history of benign prostatic hyperplasia.
Matsuda T; Fujime M; Suda K
Anal Quant Cytol Histol; 2006 Jun; 28(3):121-4. PubMed ID: 16786720
[TBL] [Abstract][Full Text] [Related]
11. Effects of a co-micronized composite containing palmitoylethanolamide and polydatin in an experimental model of benign prostatic hyperplasia.
Cordaro M; Impellizzeri D; Siracusa R; Gugliandolo E; Fusco R; Inferrera A; Esposito E; Di Paola R; Cuzzocrea S
Toxicol Appl Pharmacol; 2017 Aug; 329():231-240. PubMed ID: 28610993
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiles of lysophosphatidic acid-related molecules in the prostate: relevance to prostate cancer and benign hyperplasia.
Zeng Y; Kakehi Y; Nouh MA; Tsunemori H; Sugimoto M; Wu XX
Prostate; 2009 Feb; 69(3):283-92. PubMed ID: 19025891
[TBL] [Abstract][Full Text] [Related]
13. Aberrant Transforming Growth Factor-β Activation Recruits Mesenchymal Stem Cells During Prostatic Hyperplasia.
Wang L; Xie L; Tintani F; Xie H; Li C; Cui Z; Wan M; Zu X; Qi L; Cao X
Stem Cells Transl Med; 2017 Feb; 6(2):394-404. PubMed ID: 28191756
[TBL] [Abstract][Full Text] [Related]
14. 4. Steroid pathophysiology of BPH. Correlative morphological and biochemical investigations on the stromal tissue of the human prostate.
Bartsch G; Daxenbichler G; Rohr HP
J Steroid Biochem; 1983 Jul; 19(1A):147-54. PubMed ID: 6193337
[TBL] [Abstract][Full Text] [Related]
15. Stromal cells of the human prostate: initial isolation and characterization.
Kassen A; Sutkowski DM; Ahn H; Sensibar JA; Kozlowski JM; Lee C
Prostate; 1996 Feb; 28(2):89-97. PubMed ID: 8604397
[TBL] [Abstract][Full Text] [Related]
16. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation.
De Nunzio C; Kramer G; Marberger M; Montironi R; Nelson W; Schröder F; Sciarra A; Tubaro A
Eur Urol; 2011 Jul; 60(1):106-17. PubMed ID: 21497433
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-18 may lead to benign prostatic hyperplasia via thrombospondin-1 production in prostatic smooth muscle cells.
Hamakawa T; Sasaki S; Shibata Y; Imura M; Kubota Y; Kojima Y; Kohri K
Prostate; 2014 May; 74(6):590-601. PubMed ID: 24615654
[TBL] [Abstract][Full Text] [Related]
18. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia.
Fibbi B; Penna G; Morelli A; Adorini L; Maggi M
Int J Androl; 2010 Jun; 33(3):475-88. PubMed ID: 19508330
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor-beta is an autocrine mitogen for a novel androgen-responsive murine prostatic smooth muscle cell line, PSMC1.
Salm SN; Koikawa Y; Ogilvie V; Tsujimura A; Coetzee S; Moscatelli D; Moore E; Lepor H; Shapiro E; Sun TT; Wilson EL
J Cell Physiol; 2000 Dec; 185(3):416-24. PubMed ID: 11056012
[TBL] [Abstract][Full Text] [Related]
20. Cellular localization of fibroblast growth factor 2 (FGF-2) in benign prostatic hyperplasia.
Sinowatz F; Schams D; Einspanier R; Arnold G; Pfeffer M; Temmim-Baker L; Amselgruber W; Plendl J
Histol Histopathol; 2000 Apr; 15(2):475-81. PubMed ID: 10809367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
